NCT05367687

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Completed Phase 2 Last updated 17 November 2025

What this trial tests

Phase 2 trial testing Camrelizumab、Rivoceranib in Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation in 251 participants. Completed in 15 November 2024.

Timeline

1 September 2022

Primary endpoint
15 November 2024

15 November 2024

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	251
Start date	1 September 2022
Primary completion	15 November 2024
Estimated completion	15 November 2024
Sites	1 location across China

Drugs / interventions tested

• Camrelizumab、Rivoceranib
• Camrelizumab — full drug profile →

Conditions studied

• Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation — all drugs for Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review.
   Chamseddine S, LaPelusa M, Kaseb AO. · · 2023 · cited 17× · PMID 37444618 · DOI 10.3390/cancers15133508
2. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects.
   Guo B, Chen Q, Liu Z, Chen X, et al · · 2023 · cited 14× · PMID 37139151 · DOI 10.3389/fonc.2023.1098958
3. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
   Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, Castelló-Miralles I, et al · · 2024 · cited 10× · PMID 38817666 · DOI 10.3748/wjg.v30.i19.2512
4. Small-molecule-based targeted therapy in liver cancer.
   Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
5. Current Perspectives on Perioperative Combination Therapy for Hepatocellular Carcinoma.
   Nishio T, Yoh T, Nishino H, Ogiso S, et al · · 2025 · cited 5× · PMID 40528897 · DOI 10.1159/000546138
6. Insights in Molecular Therapies for Hepatocellular Carcinoma.
   Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831
7. Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.
   Crook CJ, Li D. · · 2023 · cited 5× · PMID 37688739 · DOI 10.1007/s11912-023-01455-9
8. Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.
   Stefanini B, Manfredi GF, D'Alessio A, Fulgenzi CAM, et al · · 2024 · cited 3× · PMID 39435480 · DOI 10.1080/17474124.2024.2419519